The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Human Parathyroid Hormone Market Research Report 2025
Synopsis
Recombinant Human Parathyroid Hormone is an artificially manufactured form of the parathyroid hormone used to treat hypoparathyroidism. Recombinant human parathyroid hormone is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures. A significant reduction in the incidence of vertebral fractures has been demonstrated.
Global Recombinant Human Parathyroid Hormone market is projected to reach US$ 228.5 million in 2029, increasing from US$ 144 million in 2022, with the CAGR of 6.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Parathyroid Hormone market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Human Parathyroid Hormone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
NPS Pharma(Shire)
Takeda
Shandong Buchang Pharmaceuticals
Ascendis Pharma
Beijing SL Pharmaceutical
Segment by Type
25 mcg/dose
50 mcg/dose
75 mcg/dose
100 mcg/dose
Segment by Application
Postmenopausal Women with Osteoporosis
Hypocalcemia in Patients with Hypoparathyroidism
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Human Parathyroid Hormone report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Recombinant Human Parathyroid Hormone is an artificially manufactured form of the parathyroid hormone used to treat hypoparathyroidism. Recombinant human parathyroid hormone is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures. A significant reduction in the incidence of vertebral fractures has been demonstrated.
Global Recombinant Human Parathyroid Hormone market is projected to reach US$ 228.5 million in 2029, increasing from US$ 144 million in 2022, with the CAGR of 6.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Parathyroid Hormone market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Human Parathyroid Hormone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
NPS Pharma(Shire)
Takeda
Shandong Buchang Pharmaceuticals
Ascendis Pharma
Beijing SL Pharmaceutical
Segment by Type
25 mcg/dose
50 mcg/dose
75 mcg/dose
100 mcg/dose
Segment by Application
Postmenopausal Women with Osteoporosis
Hypocalcemia in Patients with Hypoparathyroidism
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Human Parathyroid Hormone report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Recombinant Human Parathyroid Hormone Market Overview
1.1 Product Overview and Scope of Recombinant Human Parathyroid Hormone
1.2 Recombinant Human Parathyroid Hormone Segment by Type
1.2.1 Global Recombinant Human Parathyroid Hormone Market Value Comparison by Type (2023-2029)
1.2.2 25 mcg/dose
1.2.3 50 mcg/dose
1.2.4 75 mcg/dose
1.2.5 100 mcg/dose
1.3 Recombinant Human Parathyroid Hormone Segment by Application
1.3.1 Global Recombinant Human Parathyroid Hormone Market Value by Application: (2023-2029)
1.3.2 Postmenopausal Women with Osteoporosis
1.3.3 Hypocalcemia in Patients with Hypoparathyroidism
1.4 Global Recombinant Human Parathyroid Hormone Market Size Estimates and Forecasts
1.4.1 Global Recombinant Human Parathyroid Hormone Revenue 2018-2029
1.4.2 Global Recombinant Human Parathyroid Hormone Sales 2018-2029
1.4.3 Global Recombinant Human Parathyroid Hormone Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Recombinant Human Parathyroid Hormone Market Competition by Manufacturers
2.1 Global Recombinant Human Parathyroid Hormone Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant Human Parathyroid Hormone Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant Human Parathyroid Hormone Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant Human Parathyroid Hormone Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant Human Parathyroid Hormone, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Parathyroid Hormone, Product Type & Application
2.7 Recombinant Human Parathyroid Hormone Market Competitive Situation and Trends
2.7.1 Recombinant Human Parathyroid Hormone Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Human Parathyroid Hormone Players Market Share by Revenue
2.7.3 Global Recombinant Human Parathyroid Hormone Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Parathyroid Hormone Retrospective Market Scenario by Region
3.1 Global Recombinant Human Parathyroid Hormone Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant Human Parathyroid Hormone Global Recombinant Human Parathyroid Hormone Sales by Region: 2018-2029
3.2.1 Global Recombinant Human Parathyroid Hormone Sales by Region: 2018-2023
3.2.2 Global Recombinant Human Parathyroid Hormone Sales by Region: 2024-2029
3.3 Global Recombinant Human Parathyroid Hormone Global Recombinant Human Parathyroid Hormone Revenue by Region: 2018-2029
3.3.1 Global Recombinant Human Parathyroid Hormone Revenue by Region: 2018-2023
3.3.2 Global Recombinant Human Parathyroid Hormone Revenue by Region: 2024-2029
3.4 North America Recombinant Human Parathyroid Hormone Market Facts & Figures by Country
3.4.1 North America Recombinant Human Parathyroid Hormone Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant Human Parathyroid Hormone Sales by Country (2018-2029)
3.4.3 North America Recombinant Human Parathyroid Hormone Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Human Parathyroid Hormone Market Facts & Figures by Country
3.5.1 Europe Recombinant Human Parathyroid Hormone Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant Human Parathyroid Hormone Sales by Country (2018-2029)
3.5.3 Europe Recombinant Human Parathyroid Hormone Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Parathyroid Hormone Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Human Parathyroid Hormone Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant Human Parathyroid Hormone Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant Human Parathyroid Hormone Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Recombinant Human Parathyroid Hormone Market Facts & Figures by Country
3.7.1 Latin America Recombinant Human Parathyroid Hormone Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant Human Parathyroid Hormone Sales by Country (2018-2029)
3.7.3 Latin America Recombinant Human Parathyroid Hormone Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Parathyroid Hormone Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Parathyroid Hormone Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant Human Parathyroid Hormone Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant Human Parathyroid Hormone Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Human Parathyroid Hormone Sales by Type (2018-2029)
4.1.1 Global Recombinant Human Parathyroid Hormone Sales by Type (2018-2023)
4.1.2 Global Recombinant Human Parathyroid Hormone Sales by Type (2024-2029)
4.1.3 Global Recombinant Human Parathyroid Hormone Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Human Parathyroid Hormone Revenue by Type (2018-2029)
4.2.1 Global Recombinant Human Parathyroid Hormone Revenue by Type (2018-2023)
4.2.2 Global Recombinant Human Parathyroid Hormone Revenue by Type (2024-2029)
4.2.3 Global Recombinant Human Parathyroid Hormone Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Human Parathyroid Hormone Price by Type (2018-2029)
5 Segment by Application
5.1 Global Recombinant Human Parathyroid Hormone Sales by Application (2018-2029)
5.1.1 Global Recombinant Human Parathyroid Hormone Sales by Application (2018-2023)
5.1.2 Global Recombinant Human Parathyroid Hormone Sales by Application (2024-2029)
5.1.3 Global Recombinant Human Parathyroid Hormone Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Human Parathyroid Hormone Revenue by Application (2018-2029)
5.2.1 Global Recombinant Human Parathyroid Hormone Revenue by Application (2018-2023)
5.2.2 Global Recombinant Human Parathyroid Hormone Revenue by Application (2024-2029)
5.2.3 Global Recombinant Human Parathyroid Hormone Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Human Parathyroid Hormone Price by Application (2018-2029)
6 Key Companies Profiled
6.1 NPS Pharma(Shire)
6.1.1 NPS Pharma(Shire) Corporation Information
6.1.2 NPS Pharma(Shire) Description and Business Overview
6.1.3 NPS Pharma(Shire) Recombinant Human Parathyroid Hormone Sales, Revenue and Gross Margin (2018-2023)
6.1.4 NPS Pharma(Shire) Recombinant Human Parathyroid Hormone Product Portfolio
6.1.5 NPS Pharma(Shire) Recent Developments/Updates
6.2 Takeda
6.2.1 Takeda Corporation Information
6.2.2 Takeda Description and Business Overview
6.2.3 Takeda Recombinant Human Parathyroid Hormone Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Takeda Recombinant Human Parathyroid Hormone Product Portfolio
6.2.5 Takeda Recent Developments/Updates
6.3 Shandong Buchang Pharmaceuticals
6.3.1 Shandong Buchang Pharmaceuticals Corporation Information
6.3.2 Shandong Buchang Pharmaceuticals Description and Business Overview
6.3.3 Shandong Buchang Pharmaceuticals Recombinant Human Parathyroid Hormone Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Shandong Buchang Pharmaceuticals Recombinant Human Parathyroid Hormone Product Portfolio
6.3.5 Shandong Buchang Pharmaceuticals Recent Developments/Updates
6.4 Ascendis Pharma
6.4.1 Ascendis Pharma Corporation Information
6.4.2 Ascendis Pharma Description and Business Overview
6.4.3 Ascendis Pharma Recombinant Human Parathyroid Hormone Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ascendis Pharma Recombinant Human Parathyroid Hormone Product Portfolio
6.4.5 Ascendis Pharma Recent Developments/Updates
6.5 Beijing SL Pharmaceutical
6.5.1 Beijing SL Pharmaceutical Corporation Information
6.5.2 Beijing SL Pharmaceutical Description and Business Overview
6.5.3 Beijing SL Pharmaceutical Recombinant Human Parathyroid Hormone Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Beijing SL Pharmaceutical Recombinant Human Parathyroid Hormone Product Portfolio
6.5.5 Beijing SL Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Parathyroid Hormone Industry Chain Analysis
7.2 Recombinant Human Parathyroid Hormone Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Parathyroid Hormone Production Mode & Process
7.4 Recombinant Human Parathyroid Hormone Sales and Marketing
7.4.1 Recombinant Human Parathyroid Hormone Sales Channels
7.4.2 Recombinant Human Parathyroid Hormone Distributors
7.5 Recombinant Human Parathyroid Hormone Customers
8 Recombinant Human Parathyroid Hormone Market Dynamics
8.1 Recombinant Human Parathyroid Hormone Industry Trends
8.2 Recombinant Human Parathyroid Hormone Market Drivers
8.3 Recombinant Human Parathyroid Hormone Market Challenges
8.4 Recombinant Human Parathyroid Hormone Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
